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Introduction
Since its introduction in the 1940s, the vitamin K
antagonist warfarin is increasingly required for
prophylaxis and treatment of thrombo-embolism.
There is wide variation in dosage from individual to
individual and dose is subject to adjustment due to
interactions with other medications, alcohol and
foods. It is therefore important to monitor warfarin
therapy as outside the therapeutic range either serious
bleeding or failure to prevent thrombo-embolism may
occur. There are also several adverse skin manifesta-
tions associated with the use of anticoagulants, ran-
ging from ecchymoses and purpura, haemorrhagic
necrosis, maculopapular vesicular urticarial eruptions
to purple toes. Warfarin induced skin necrosis (WISN)
was first described in 1943.1 To date approximately
300 cases have been reported worldwide.2
Report
A 51-year-old lady developed a deep venous throm-
bosis 4 weeks post hysterectomy and was commenced
on an intravenous heparin infusion (APTT100) and
prescribed warfarin with daily blood coagulation
checks. On day 6 the INR was therapeutic and the
heparin infusion stopped. On day 7, the patient com-
plained of pain in the lower abdomen, with some black
discolouration and cutaneous blistering measuring
156 cm over the lower abdomen. An abdominal CT
scan revealed stranding of the subucutaneous fat in
both flank regions with no focal underlying haema-
toma. The wound sloughed and the necrotic area of
breakdown required surgical debridement (Fig. 1).
Biopsies of the area confirmed areas of necrosis, haem-
orrhage and fibrin deposition in the post capillary
venules consistent with warfarin induced skin necro-
sis. Blood was sent for a thrombophilia screen and
results revealed protein S deficiency. The patient was
discharged on daily innohep injections (175 iu/Kg).
She is currently making good progress.
Discussion
Warfarin induced skin necrosis (WISN) is an uncom-
mon complication of anticoagulation therapy that
occurs in 1 in 1000 to 1 in 10 000 people starting
Fig. 1. Warfarin induced skin necrosis.
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warfarin.3 It is characterized by skin and subcu-
taneous tissue death that usually occurs 3±6 days
after initiating warfarin therapy. WISN is often asso-
ciated with a large initial loading dose of warfarin. It is
thought to be due to a rapid elimination of protein C
(a natural anticoagulant) compared to other vitamin
K-dependent clotting factors. WISN is mainly seen in
middle aged, peri-menopausal, and obese women.2
The female to male ratio is 4:1. The sites of the lesions
are random and unpredictable, but the most common
sites appear to be fatty areas such as breast, buttocks,
and thighs.4 Lesions are painful and hemorrhagic, and
they can develop suddenly and rapidly. WISN is best
treated by withdrawal of warfarin with substitution
by either intravenous heparin or subcutaneous
injection of low molecular weight heparin. Only a
few cases of WISN have been reported to be asso-
ciated with protein S deficiency.5 Although its precise
pathogenesis is unclear, warfarin induced skin
necrosis is a well-established complication of warfarin
therapy. The associated morbidity is high, regularly
requiring surgical intervention. Failure of early diag-
nosis and treatment may result in death. Knowledge
of the condition should permit the physician to make
an early diagnosis and thus limit the resultant mor-
bidity. Suspicion of warfarin induced skin necrosis in
a patient should raise the possibility of an inherited
thrombophilia, and lead to appropriate investigations.
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